Updated through December 31, 2002
|NDA Number||Proprietary Name||Established Name||Applicant||Review Classification||Approval Date||Indication|
|N021232||Orfadin||Nitisinone||Swedish Orphan||P, O||18-Jan-02|| |
Orfadin provides for the use for adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.
|N021286||Benicar||Olmesartan Medoxomil||Sankyo||S||25-Apr-02||Benicar is indicated for the treatment of hypertension.|
|N021344||Faslodex||Fulvestrant||AstraZeneca||S||25-Apr-02||Faslodex is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.|
|N021272||Remodulin||Treprostinil Sodium||United Therapeutics||P, O||21-May-02||Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH).|
|N021266||Vfend||Voriconazole||Pfizer||S||24-May-02||Vfend is indicated for the treatment of invasive aspergillosis and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp., including Fusarium solani, in patients intolerant of, or refractory to, other therapy.|
|N021191||Imagent||Perflexane Phospholipid Microspheres||Alliance Pharm||S||31-May-02||Imagent is indicated for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.|
|N021196||Xyrem||Sodium Oxybate||Orphan Medical||P, O||17-Jul-02||Xyrem is indicated for the treatment of cataplexy associated with narcolepsy.|
|N021200||Zelnorm||Tegaserod Maleate||Novartis Pharms||P||24-Jul-02||Zelnorm is indicated for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.|
|N021492||Eloxatin||Oxaliplatin||Sanofi-Synthelabo||P||09-Aug-02||Eloxatin is indicated in combination with infusional 5-FU/LV for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/LV and irinotecan.|
|N021449||Hepsera||Adefovir Dipivoxil||Gilead Sciences||P||20-Sep-02||Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) or histologically active disease.|
|N021437||Inspra||Eplerenone||GD Searle||S||27-Sep-02||Inspra is indicated for the treatment of hypertension, alone or in combination with other agents.|
|N021445||Zetia||Ezetimibe||MSP Singapore||S||25-Oct-02||Zetia is indicated for (1) Primary hypercholesterolemia - as adjunctive therapy to diet for reduction of elevated total-C, LDL-C and Apo B in patients with primary (heterozygous familial and non-familial) hypercholestrolemia either alone or with an HMG-Co A reductase inhibitor. (2) Homozygous familial hypercholesterolemai - in combination with either atorvastatin or simvastatin, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or, if such treatments are unavailable, in combination with either atorvastatin or simvastatin alone. (3) Homozygous familial sitosterolemia - as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels.|
|N021436||Abilify||Aripiprazole||Otsuka||S||15-Nov-02||Abilify is indicated for the treatment of schizophrenia.|
|N021498||Alinia||Nitazoxanide||Romak Labs||P, O||22-Nov-02||Alinia is indicated for the treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia.|
|N021411||Strattera||Atomoxetine Hydrochloride||Eli Lilly||S||26-Nov-02||Strattera is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) for children and adolescents ages 6-18 and adults.|
|N021321||Extraneal||Icodextrin||Baxter Healthcare||S, O||12-Dec-02||Extraneal is indicated for a single daily exchange for the long (8-16-hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.|
|N021016||Relpax||Eletriptan Hydrobromide||Pfizer||S||26-Dec-02||Replax is indicated for the acute treatment of migrane.|
P - Priority Review - Significant improvement compared to marketed products, in the treatment, diagnosis, or prevention of a disease.
S - Standard Review - Products that do not qualify for priority review.
O - Orphan Designation - Pursuant to Section 526 of the Orphan Drug Act (Public Law 97-414 as amended).